New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
12:18 EDTGILDGilead announces 24-week Phase 2 results for once-daily HIV regimen
Gilead Sciences announced detailed 24-week results from a Phase 2 study evaluating a once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection. A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg was found to be similar to Stribild based on the percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks of treatment. These findings were presented today in a latebreaker session at the 20th Conference on Retroviruses and Opportunistic Infections taking place in Atlanta. In Study 102, HIV-positive treatment-nave adult patients were randomized to receive the investigational TAF-based regimen or Stribild. At 24 weeks, 87% of patients taking TAF and 90% of patients taking Stribild achieved HIV RNA less than 50 copies/mL, based on the FDA snapshot algorithm. There were no statistically significant differences in the frequency and nature of Grades 3-4 laboratory abnormalities, and the frequency and nature of adverse events were similar between the two arms. Both regimens were generally well tolerated.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
November 24, 2015
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB BAC DIS NFLX X YNDX GILD PANW SUNW
November 23, 2015
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
06:41 EDTGILDGilead granted marketing authorization in EU for Genvoya
Subscribe for More Information
November 18, 2015
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
November 17, 2015
10:47 EDTGILDBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
November 16, 2015
09:04 EDTGILDGilead says Phase 3 Zydelig study shows 'clinical benefit'
Gilead announced that its Phase 3 Study 115 evaluating Zydelig added to standard therapy in previously-treated chronic lymphocytic leukemia patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival and overall survival in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in Orlando, Florida taking place December 5-8. "The clinical benefit observed in this Phase 3 study adds to the body of evidence demonstrating the potential of Zydelig-containing treatment regimens for patients with previously treated CLL," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to sharing the detailed scientific data with the hematology community at the upcoming ASH meeting."
November 15, 2015
20:17 EDTGILDGilead presents results from four Phase 3 studies of sofosbuvir/velpatasvir
Subscribe for More Information
15:47 EDTGILDGilead reports data from multiple studies of Viread, TAF, others
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use